← 產業報告目錄
Real World Evidence (RWE) Oncology Market Size, Share & Trends Analysis Report By Component (Real-world Datasets, RWE Consulting & Analytics Services), Application (Drug Development & Approvals, Market Access, Post-market Surveillance), End User, By Region, And By Segment Forecasts, 2025-2034.
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-03-19頁數 170報告編號 INSIGHTACE-81b83ef600
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 772.5 Mn as of 2024, the global Real World Evidence (RWE) Oncology Market is poised to climb to USD 2,373.9 Mn by 2034, reflecting a compound annual growth rate of 12.1% over the 2025–2034 period.
Real World Evidence (RWE) Oncology encompasses term used in the healthcare industry to describe data and information obtained from patient experiences, real-world clinical practice, and other non-clinical study sit. The sector has gained traction as organizations seek innovative approaches to address evolving healthcare challenges.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the escalating emphasis on efficiency and sustainability within the healthcare sector.
From a segmentation standpoint, the market is categorized across multiple dimensions including product type, application, end-user, and geography, each exhibiting distinct growth patterns and opportunities.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RWE Oncology Market Snapshot
Chapter 4. Global RWE Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global RWE Oncology Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on RWE Oncology Market Industry Trends
Chapter 5. RWE Oncology Market Segmentation 1: By Component, Estimates & Trend Analysis
5.1. Market Share by Component, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Component:
5.2.1. Datasets
5.2.1.1. Disparate Datasets
5.2.1.2. EMR/EHR/Clinical Data
5.2.1.3. Claims & Billing Data
5.2.1.4. Pharmacy Data
5.2.1.5. Cancer Registries
5.2.1.6. Other Disparate Datasets
5.2.1.7. Integrated Datasets
5.2.2. Consulting Services
Chapter 6. RWE Oncology Market Segmentation 2: By Application, Estimates & Trend Analysis
6.1. Market Share by Application, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
6.2.1. Drug Development & Approvals
6.2.2. Market Access & Reimbursement/Coverage Decisions
6.2.3. Medical Device Development & Approvals
6.2.4. Post-market Surveillance
6.2.5. Other Applications
Chapter 7. RWE Oncology Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End User:
7.2.1. Pharmaceutical, Biotechnology, and Medical Device Companies
7.2.2. Healthcare Payers
7.2.3. Healthcare Providers
7.2.4. Other End Users
Chapter 8. RWE Oncology Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global RWE Oncology Market, Regional Snapshot 2024 & 2034
8.2. North America
8.2.1. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.2.3. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.2.4. North America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.3. Europe
8.3.1. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.3.3. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.3.4. Europe RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.4. Asia Pacific
8.4.1. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.4.3. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.4.4. Asia Pacific RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.5. Latin America
8.5.1. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.5.3. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.5.4. Latin America RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
8.6. Middle East & Africa
8.6.1. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Component, 2021-2034
8.6.3. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by Application, 2021-2034
8.6.4. Middle East & Africa RWE Oncology Market Revenue (US$ Mn) Estimates and Forecasts by End User, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. IQVIA Holdings Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Component/Service
9.2.1.3. Financial PerApplicationance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Veracyte, Inc.
9.2.3. Flatiron Health, Inc.
9.2.4. IBM Corporation
9.2.5. Oracle Corporation
9.2.6. SAS Institute Inc.
9.2.7. ICON plc
9.2.8. Parexel International Corporation
9.2.9. Syneos Health, Inc.
9.2.10. Cognizant Technology Solutions Corporation
9.2.11. UnitedHealth Group Incorporated
9.2.12. Anthem, Inc.
9.2.13. Clinigen Group plc
9.2.14. PerkinElmer, Inc.
9.2.15. Tempus Labs, Inc.
9.2.16. Other Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們